First UK patients receive experimental mRNA therapy for cancer in global trial
The phase 1/2 Mobilize trial is evaluating the safety and efficacy of mRNA-4359
Read More
Tag: mRNA-4359
- Cellistic launches new iPSC-based platforms to expand immuno-oncology therapies
- Fabentech secures French approval for Ricimed antidote
- Oxford Drug Design reports major in vivo milestone for novel cancer therapy
- Storm Therapeutics and AlidaBio launch collaboration to advance RNA‑targeting cancer therapies
- Excellence adventure
